I actually don’t think I saw any of your posts talking specifically about puberty blockers, so thank you for summarizing.

I am not sure what you mean by “missed time” and “runs its remaining time out.” GNRH agonists work by downregulating the pituitary gland, which results in decreased hormone secretion. When those hormones stop, so does puberty. When those hormones resume, puberty resumes, typically 6-18 months after stopping the med. There is no magical set of checkboxes or hidden time schedule the body must follow: the entire process is hormone-mediated. “Arrest” is the correct medical term to describe this process, though “pause” is a good non-medical substitute.

You are incorrect about the dosing: it is comparable to that for use in other conditions. For example, for leuprolide (one of the most common meds used,) the starting dose is 3.25 mg per month or 11.25 mg every 3 months with a max of 22.5 mg every 3 months. This is comparable to the dosing for adolescent endometriosis and fibroids, and lower than the dosing for central precocious puberty (7.5-15 mg monthly or 11.5-30 mg every 3 months.)

Leuprolide has been used in children as young as 1 year old and can be continued until 11 or 12 for central precocious puberty. Endometriosis and fibroids are teen indications, so it has been used for children of all ages (as well as adults of all ages.) The result and intended effect are the same as central precocious puberty or for kids with growth hormone deficiency: to arrest puberty temporarily, at which point it can be safely resumed. The big difference is that the blocking for precocious puberty happens much earlier and for much longer, while the blocking for growth hormone deficiency happens at the same time (start of puberty.)

It’s important to note that people who take a treatment are not “test subjects.” Test subjects are those enrolled in clinical trials. They are given informed consent related to the trial, enrolled with strict parameters, and followed-up on in a systematic way. “Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron” (2022) is an example of a study that used test subjects. You going to the doctor and getting a medication is not.

I’m willing to wager that you were perfectly fine letting endocrinologists use their medical expertise to judge whether giving medications like leuprolide to toddlers and young children is medically necessary, and that your objection to it and similar meds magically appeared when those same doctors judged it medically necessary to give these same medications to transgender early teens. If this is indeed the case, it raises the question of whether you’re actually concerned about these medications, or whether you’re actually using it as an excuse to block access to safe and effective medical treatments for trans teens.